SCHEMBL26700970

SCHEMBL26700970

CC(C)CCCCNC(=O)CCOCCOCCNC(C)C

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.40
GLP1R P43220 8/20 0.38
TSHR P16473 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 3/20 0.37
POLB P06746 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.36
PKM P14618 1/20 0.36
CASP2 P42575 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
NAMPT P43490 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29299850 1.00 HPGD (0.40) HPGDGLP1RTSHRMEN1KMT2A
SCHEMBL23319057 1.00 HPGD (0.40) HPGDGLP1RTSHRMEN1KMT2A
SCHEMBL23320101 0.99 GLP1R (0.40) HPGDGLP1RTSHRMEN1KMT2A
SCHEMBL29299838 0.99 HPGD (0.41) HPGDGLP1RTSHRMEN1KMT2A
SCHEMBL29299575 0.96 HPGD (0.41) HPGDGLP1RTSHRMEN1KMT2A
SCHEMBL25792664 0.94 HPGD (0.42) HPGDGLP1RTSHRMEN1KMT2A
SCHEMBL26866029 0.92 GLP1R (0.42) HPGDGLP1RTSHRMEN1KMT2A
SCHEMBL25480495 0.89 CNR1 (0.44) HPGDGLP1RTSHRMEN1KMT2A
SCHEMBL26034458 0.89 TSHR (0.41) HPGDTSHRMEN1KMT2AKDM4E
SCHEMBL20466152 0.88 MEN1 (0.44) HPGDGLP1RTSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348452-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, BRCA1 HPGD 3620/4885GLP1R 4388/4885TSHR 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.